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PhosphorylationVoltage-dependent anion channels are abundant mitochondrial outer membrane proteins expressed in three
isoforms, VDAC1-3, and are considered as “mitochondrial gatekeepers”. Most tissues express all three iso-
forms. The functions of VDACs are several-fold, ranging from metabolite and energy exchange to apoptosis.
Some of these functions depend on or are affected by interaction with other proteins in the cytosol and inter-
membrane space. Furthermore, the function of VDACs, as well as their interaction with other proteins, is af-
fected by posttranslational modiﬁcation, mainly phosphorylation. This review summarizes recent ﬁndings on
posttranslational modiﬁcation of VDACs and discusses the physiological outcome of these modiﬁcations. This
article is part of a Special Issue entitled: VDAC structure, function, and regulation of mitochondrial
metabolism.
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Beyond being the “powerhouses” of the cell, mitochondria are in
constant communication with the rest of the cell. This bidirectional
communication involves the continuous exchange of material and in-
formation. Each mitochondrion is bounded by two membranes, outer
and inner, yielding six distinct domains, the outer membrane, inner
boundary membrane, intermembrane space, cristal membrane, intra-
cristal space, and matrix. The exchange between the cytosol and mi-
tochondrial matrix can take place because the inner mitochondrialtructure, function, and regula-
niversity School of Medicine,
SA. Tel.: +1 216 368 3147;
el).
sevier B.V.membrane contains speciﬁc transport proteins that catalyze the uni-
or bidirectional ﬂow of metabolites and ions [1,2]. The mitochondrial
outer membrane contains channel-forming proteins, which harbor β-
barrel structures, i.e., Tom40, Sam50, Mdm, and VDAC [3,4], of which
the latter is the most abundant. Signaling to and from the mitochon-
dria involves posttranslational modiﬁcation of both mitochondrial
and extramitochondrial proteins as well as translocation/association
of proteins with mitochondria. A detailed compilation of
mitochondria-associated kinases, phosphatases, and other proteins
is presented in Table 1 in Ref. [5].
In mammals, voltage-dependent anion channels (VDACs) are
expressed in three different isoforms [6]. By comparing the expres-
sion of VDAC isoforms in rat liver, kidney, heart, and brain, it was con-
cluded that in mammalian tissues VDAC1 is the most abundantly
expressed isoform [7]. VDACs present in abundance in the mitochon-
drial outer membrane also are abundant in the plasma membrane. In-
deed, VDAC, ﬁrst isolated from human lymphocytes by Thinnes et al.
1521J. Kerner et al. / Biochimica et Biophysica Acta 1818 (2012) 1520–1525[8], recently was shown to be present in the plasma membrane of a
variety of cells [9], and to have manifold functions in the mitochon-
drial outer membrane. By forming pores, VDACs are involved not
only in metabolite and energy exchange between the cytosol and mi-
tochondria [10], but possibly in formation of the permeability transi-
tion pore [11]. Furthermore, VDACs also are docking sites for cytosolic
proteins such as hexokinase [12], cytoskeletal proteins such as tubu-
lin [13], and microtubule-associated protein 2 (MAP2) [14], as well
as proapoptotic proteins [15,16]. The aforementioned functions of
VDACs are discussed in detail in different reviews presented in this
issue of Biochimica Biophysica Acta.
Despite the critical involvement of VDACs in various mitochondri-
al functions, relatively little is known as to how VDACs are regulated
and how they fulﬁll their roles. In addition to expression of three iso-
forms and tissue-speciﬁc splice variants of VDAC3 [17,18], a possible
mechanism for the diverse physiological roles of these channel pro-
teins is that of reversible posttranslational modiﬁcation. However,
only very few mass spectrometric studies targeting posttranslational
modiﬁcations of the different VDAC isoforms currently are available.
What information is available on posttranslational modiﬁcations, spe-
ciﬁcally phosphorylation and acetylation, of VDACs is based on stud-
ies directed at posttranslational modiﬁcation of VDACs [19] or on
shotgun proteomic approaches on fractions enriched in phosphopep-
tides and acetyllysine-containing peptides [20–27]. These studies do
not relate posttranslational modiﬁcations to altered function. Phos-
phorylation of VDACs often is inferred from studies employing immu-
noblotting that use anti-phosphoserine, -threonine, and -tyrosine
antibodies analysis [vide infra].
In this review, we summarize ﬁndings in the literature regarding
the different posttranslational modiﬁcations of VDACs and discuss
the effect of modiﬁcation on their function.
2. Posttranslational modiﬁcation of VDACs
Reversible posttranslational modiﬁcations (PTM) play an impor-
tant regulatory role in mitochondrial function, among others. Such
modiﬁcations do not simply affect enzymatic activity by switching ac-
tivity on and off but also impact degradation of proteins, translocation
of proteins from one compartment to another within the cell, as well
as docking or interacting with other proteins. In addition, PTM is crit-
ical in cell signaling processes. Among the numerous posttranslation-
al modiﬁcations, reversible phosphorylation is the most frequent andTable 1
Phosphorylation of VDAC isoforms determined by mass spectrometry (MS) or site-directed
Isoform Phosphorylation (species/organ) Method [Ref.] Can
VDAC1 S12, 136 (RLM) MS [19] GSK
S12, 103 (HMEC) SDM [48] GSK
*S117 (MB; MLM) MS [20,21] CKI/
S101, 102, 104 ; HeLa cells MS [44] GSK
CKI/
S193 (HK2) SDM [51] Nek
T107; HeLa cells MS [44] PKC
Y80, 208; MB MS [22] SRC
VDAC2 S115; HeLa cells MS [44] CKI/
T118; HeLa cells MS [44] PKC
Y237; RLM MS [19] INSR
Y207; MB MS [22] EGF
VDAC3 S241; RLM MS [19] PKA
T33; RLM MS [19] PKC
Y49; MB MS [22] CKII
Abbreviations: RLM = rat liver mitochondria; MLM = mouse liver mitochondria; MB = m
renal tubular epithelial cells; HK = hexokinase.
a Determined using NetPhosK 1.0 Server.
* Note added in proof: Mouse VDAC1 sequence was taken from the PubMed protein sequ
Ujwal et al. (R. Ujwal, D. Cascio, J.-P. Colletier, S. Faham, J. Zhang, L. Toro, P. Ping, J., J. Abramso
into metabolite gating, Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 17742–17747). This would mbest studied. It has been estimated that more than one-third of all
proteins are phosphorylated, either at one or multiple sites [28,29].
Protein phosphorylation is catalyzed by a family of protein kinases,
with serine, threonine, and tyrosine side chains being the most fre-
quently modiﬁed [30]. The reverse reaction is catalyzed by speciﬁc
protein phosphatases, i.e., phosphoserine/phosphothreonine-speciﬁc
and phosphotyrosine-speciﬁc families of phosphatases [31].
Another frequent PTM is protein acetylation, with the number of
acetylated proteins rivaling that of phosphorylated proteins. The
two types of acetylation are N-terminal acetylation and lysine side-
chain acetylation. The former is irreversible and occurs co- and post-
translationally and is catalyzed by N-acetyltransferases. N-terminal
acetylation is prevalent in higher organisms and occurs on N-
terminal methionine or on the newly terminal amino acid residue
after removal of the N-terminal methionine [32–34]. The biological
signiﬁcance of N-terminal acetylation has not been fully elucidated;
it is thought to affect protein stability, assembly, and location [34]. Re-
versible acetylation of lysine ε-amino groups is catalyzed by protein
acetyltransferases (PATs) and deacetylases or histone deacetylases
(HDACs) and takes place posttranslationally [35,36]. The latter pro-
teins are grouped into class I and II HDACs; class III deacetylases are
termed “sirtuins”[36]. The signiﬁcance of reversible lysine acetylation
of histone proteins is well-appreciated; its importance in intermedi-
ary metabolism is just becoming apparent [26,37–39].
2.1. Phosphorylation of VDACs determined by mass spectrometry
There are only a very limited number of studies directed at PTM of
VDAC, including that of phosphorylation, by means of mass spectrom-
etry. The sites modiﬁed on VDAC isoforms are listed in Table 1 along
with candidate protein kinases catalyzing the phosphorylation and
the functional outcome of phosphorylation where determined. A pos-
sible reason for the limited number of studies is that VDACs are highly
hydrophobic integral mitochondrial outer membrane proteins and
difﬁcult to work with. To overcome this obstacle, we developed a
method to study the PTM of integral rat liver mitochondrial outer
membrane proteins [40]. The method is based on enrichment of the
proteins by ﬁrst harvesting high-purity outer membrane from rat
liver mitochondria, followed by isolation of the proteins of interest
by semipreparative SD-PAGE/electroelution. Applying this method
to VDACs in rat liver mitochondria, we have shown that all three
VDAC isoforms are expressed in these organelles. In addition, allmutagenesis (SDM) and functional consequences of VDAC phosphorylation.
didate protein kinasesa Effect of phosphorylation [Ref.]
3/CaM-II/CKI Not determined
3/CaM-II/CKI; CKI Sensitization to apoptosis via inhibition of
phosphorylated VDAC1 degradation [48].
p38MAPK Not determined
3/cdc2/CaM-II; PKC/cdc2/GSK3;
p38MAPK/GSK3
Not determined
1/PKC Prevention of cell death [51].
/GSK3/CaM-II Not determined
/EGFR; EGFR/SRC/INSR Not determined
cdk5/GSK3 Not determined
/CKI/GSK3 Not determined
/EGFR/SRC Not determined
R/SRC/INSR Not determined
/GSK3/CaM-II Not determined
/CaM-II/GSK3 Not determined
/GSK3/CaM-II Not determined
ouse brain; HMEC = human microvascular endothelial cells; HK2 = human proximal
ence. However, the ﬁrst 13 amino acids are not present in the sequence published by
n, The crystal structure of mouse VDAC1 at 2.3A resolution reveals mechanistic insights
ake the serine of interest 104.
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shown in Table 1, VDAC1 is phosphorylated on serine 12 and 136, cor-
responding to CaM-II/GSK3 and PKC consensus sites, respectively
[19]. These in situ ﬁndings on VDAC1 phosphorylation are supported
by in vitro studies. It has been shown that GSK3 is able to phosphory-
late isolated VDAC; neither the isoform nor the phosphorylated resi-
due was identiﬁed [41]. In another study using in vitro transcribed
and translated VDAC (isoform not speciﬁed), it was shown that
GSK3β phosphorylates wild-type VDAC, but not the mutated form
where threonine 51 was altered to alanine [42]. Regarding the phos-
phorylation of VDAC by PKC, it was shown that PKCε directly interacts
with and phosphorylates VDAC1 [43]; the amino acid residue phos-
phorylated by PKCε was not identiﬁed.
In addition to documentation of serine 12 and 136 phosphorylation,
VDAC1 in mouse liver mitochondria was found in two other studies to
be serine-phosphorylated, and in a study of HeLa cells serine- and
threonine-phosphorylated. Employing an improved immobilized
metal afﬁnity chromatography (IMAC) method to examine mouse
liver mitochondrial phosphoproteome, Lee et al. documented the phos-
phorylation of serine 117 [21]. The same serine residue was found by
Munton et al. to be phosphorylated in synaptosomal preparations
[20]. In HeLa cells, the same peptide is phosphorylated on serine 101,
102, and 104, as well as on threonine 107 [44]. All three studies used
shotgun proteomic approaches; the phosphopeptide-enriched fractions
were analyzed bymass spectrometry. In a study that used a shotgun ap-
proach, VDAC1 was shown to be phosphorylated on tyrosine residues
80 and 208 [22]. In the latter report, tyrosine-phosphorylated peptides
were enriched by employing immobilized antiphosphotyrosine anti-
bodies and the resultant fraction analyzed.
Besides VDAC1 being the most abundant isoform, VDAC2 phos-
phorylation was demonstrated in three studies. Olsen et al. demon-
strated that in HeLa cells VDAC2 is phosphorylated on serine 115
and threonine 118 [44]. Deng et al. have reported that in rat liver mi-
tochondria VDAC2 is phosphorylated on threonine 109 [23]. Howev-
er, the reported amino acid sequence (LpTLDTTSSPNTGK) does not
match any protein in the ExPASy Proteomics Server's database. We
have shown in our mass spectrometric study targeting VDACs that ty-
rosine 237 is phosphorylated [19]. In a subsequent study of the tyro-
sine phosphoproteome in mouse brain, Ballif et al. documented
tyrosine phosphorylation on residue 207 [22].
Phosphorylation of VDAC3 in rat liver mitochondria of serine 241
and threonine 33 was previously shown by us [19]. These sites corre-
spond to PKA and PKC consensus sites. As mentioned above, PKCε can
be recruited to mitochondria where it associates with and phosphor-
ylates VDAC1. Whether or not it also phosphorylates VDAC3 remains
to be determined. PKA is known to be present in mitochondria — in
vitro studies have shown that it phosphorylates VDAC resulting in al-
tered gating properties [45,46]. In rat brain, VDAC3 also is tyrosine-
phosphorylated at residue 49 [22].
Table 1 is a summary of in situ phosphorylation of VDAC isoforms
along with possible candidate protein kinases and references. These
studies were directed at the determination of phosphorylation sites
in VDACs or examination of the mitochondrial phosphoproteome
usingmass spectrometry. The functional relevance of these posttrans-
lational modiﬁcations by phosphorylation was not addressed.
2.2. Effect of VDAC phosphorylation on its function
VDACpuriﬁed either fromrat liver or rat brainmitochondria is phos-
phorylated in vitro by cAMP-dependent protein kinase A (PKA) [45,46].
Following reconstitution of VDAC into planar lipid bilayers, phosphory-
lation by PKA reduces the channel current. These in vitro data reinforce
the importance of protein phosphorylation in the regulation of VDACs
but do not reveal which amino acid residue is phosphorylated.
Relatively few in vivo or in situ studies on VDACs phosphorylation
are available. Most studies linking phosphorylation of VDAC tofunction employed immunoblotting with antiphospho-serine,
-threonine, and -tyrosine antibodies; a few reports used
phosphosite-speciﬁc antibodies. Most of these studies focused on
VDACs' role in apoptosis. Although VDACs are not considered to be es-
sential components of the mitochondrial permeability pore (mPTP)
[47], there is substantial evidence for at least an indirect role of
VDAC phosphorylation in apoptosis. Yuan et al. have shown that endo-
statin, a powerful inhibitor of angiogenesis in tumors, promotes the
opening of themitochondrial permeability transition pore via amech-
anism that involves VDAC1 [48]. Accordingly, silencing or overexpres-
sion of VDAC1 respectively attenuates or increases the sensitivity of
endothelial cells to endostatin-induced apoptosis. Simultaneously
with promoting the opening of PTP, endostatin decreases the amount
of hexokinase 2 and increases the content of VDAC1. Because hexoki-
nase binding to VDAC decreases its phosphorylation, the authors spec-
ulated that endostatin-induced increase in VDAC1 is due to
phosphorylation and consequent inhibition of its degradation. Indeed,
mutation of serine 12, previously shown by us to be phosphorylated in
situ, and serine 103 effectively attenuated the endostatin-induced
upregulation of VDAC1, and abolished PTP opening and caspase 3 ac-
tivation in endothelial cells. Furthermore, in support of inhibition of
VDAC1 degradation by phosphorylation, the effect of serine 12 and
103mutation to alanine VDAC1 level was inhibited by the proteasome
inhibitor, MG132. A polar opposite effect of VDAC1 phosphorylation
on cell death was reported by Sun et al. [49]. According to these au-
thors, overexpression of both hexokinase isoforms (hexokinase I and
II) in HEK293 cells protected against cell death and inhibited mPTP
opening in response to hydrogen peroxide. Furthermore, hexokinase
expression increased VDAC phosphorylation, which was signiﬁcantly
decreased by a PKCε inhibitor peptide. These authors proposed that
PKCε-dependent VDAC phosphorylation protects against cell death.
However, the VDAC isoform that becomes phosphorylated in a
hexokinase-dependent manner by PKCε has not been speciﬁed nor
the phosphorylated amino acid residue determined.
The involvement of VDACs in cell death has been suggested by stud-
ies using the ischemic reperfused heart. Subjecting rabbit hearts to is-
chemia by ligation of the left descending coronary artery for 60 min
followed by reperfusion results in necrosis and apoptosis that is pre-
vented by the p38 MAP kinase inhibitor, PD169316 [50]. Associated
with increased apoptosis was a signiﬁcant increase in tyrosine phos-
phorylation of VDAC1, as assessed by immunoblotting with phospho-
tyrosine antibodies. This increase in tyrosine phosphorylation is
prevented by the p38 MAP kinase inhibitor; concomitant with inhibi-
tion of p38 there was signiﬁcant cardioprotection. Because p38MAP ki-
nase is a serine/threonine kinase, explanation of tyrosine-
phosphorylation of VDAC1 requires the involvement of a downstream
tyrosine kinase. Alternatively, the protective effect of p38 MAP kinase
inhibitor might be due to phosphorylation of serine/threonine resi-
due(s), since only tyrosine phosphorylation was investigated in the
study. Neither the downstream tyrosine kinase nor the tyrosine residue
that becomes phosphorylated during ischemia/reperfusion was identi-
ﬁed. These data emphasize the involvement of VDAC1 in apoptosis.
Findings with HeLa cells are consistent with the proapoptotic na-
ture of phosphorylated VDAC1 [42]. The protective effect against
cell death of hexokinase binding to mitochondria is mediated via
Akt, a protein kinase also known to localize to the mitochondria and
to be regulated by the upstream phosphatidylinositol-3-kinase. Acti-
vation of Akt phosphorylates GSK3β, also known to localize to mito-
chondria, inhibits its enzymatic activity. As a consequence, GSK3β
cannot phosphorylate VDAC, thus permitting hexokinase-binding to
VDAC. Accordingly, preventing the activation of Akt by inhibiting
the upstream phosphatidylinositol-3-kinase by wortmanin, or inhi-
biting Akt by the Akt inhibitor IV disrupted hexokinase binding to mi-
tochondria. Immunoprecipitation of VDAC1 from cells treated with
either wortmanin or Akt inhibitor IV followed by immunoblotting
with anti-phosphothreonine antibodies revealed strong reactivity
Table 2
Posttranslation modiﬁcation of VDACs by epsilon lysine acetylation.
Isoform Acetylation (species/organ) Effect of acetylation Ref.
VDAC1 K33, 41, 74, 234 (mouse liver mitochondria) Not determined [24]
K42, 122, 132 (mouse liver mitochondria) Not determined [25]
K237 (mouse liver and heart) Not determined [63]
K28 (human liver) Not determined [26]
VDAC2 K32, 75 (mouse liver mitochondria) Not determined [24]
K121 (mouse liver mitochondria) Not determined [25]
VDAC3 K20, 61, 226 (mouse liver mitochondria) Not determined [24]
K63, 109 (mouse liver mitochondria) Not determined [25]
K28 (human liver) Not determined [26]
Analysis was based on isolated mitochondria or on whole tissue homogenates.
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was silenced or threonine 51 was mutated to alanine (threonine 51
is in GSK3β phosphorylation consensus). Although these studies are
consistent with phosphorylation of VDAC1, the question remains as
to which amino acid in VDAC is phosphorylated. Phosphorylation of
serine residues also was not assessed in the study despite GSK3β
being a serine/threonine kinase.
In contrast to the foregoing report, Das et al. implicated VDAC2
rather than VDAC1 in ischemia/reperfusion injury, and proposed a
mechanism that does not involve opening of the mPTP [41]. Using
the Langendorf perfused rat heart, the authors demonstrated signiﬁ-
cantly improved recovery of cardiac function in the presence of the
GSK inhibitors, SB 216763 and SB 415286. The improvement in recov-
ery was associated with decreased phosphorylation of VDAC, as eval-
uated by immunoblotting (isoform-speciﬁcity of the VDAC antibodies
not speciﬁed). Following in-gel digestion of the relevant spots, mass
spectrometric analysis revealed the presence of VDAC2. It is not
clear from the data presented whether other proteins, especially the
other VDAC isoforms, also were present in the excised gel plugs. Fur-
thermore, direct demonstration of VDAC2 phosphorylation, i.e., iden-
tiﬁcation of the phosphorylated residue(s), was not provided.
At variance with the proposed proapoptotic feature of VDAC phos-
phorylation are ﬁndings by Chen et al. [51]. Studying the mechanism
by which mammalian NIMA-related protein kinase (Nek1) protects
against cell death, the authors found that protection against apoptosis
is contingent on VDAC1 phosphorylation on serine residue 193,
which is easily accessible from the cytosolic side of the mitochondrial
outer membrane. Accordingly, ectopic expression of the non-
phosphorylatable S193A VDAC1 mutant resulted in cell death. Con-
versely, ectopic expression of the S193Q VDAC1 mutant, in which
phosphorylation is mimicked by glutamate, prevented mitochondrial
membrane permeabilization and averted cell death. Evidence for
Nek1 as the protein kinase responsible for VDAC1 phosphorylation
was provided by expressing a dominant-negative, kinase-dead Nek1
mutant (K33A) in different cell lines. Expression of the mutant
NEK1, but not the wild-type, resulted in mitochondrial cell death.
This is preceded by lack of serine 193 phosphorylation, as determined
by immunoblotting with antibodies, which speciﬁcally recognize the
serine 193 phosphorylated form of VDAC1. Although Nek1 is localized
predominantly in the cytosol, a signiﬁcant fraction is found associated
with mitochondria. The direct physical interaction between Nek1 and
VDAC1 was demonstrated using a yeast two-hybrid system and recip-
rocal immunoprecipitation using anti-VDAC1 and anti-Nek1
antibodies.
In addition to the aforementioned studies, phosphorylation of
VDACs has been reported to occur in pathological conditions. In post-
mortem brain from Alzheimer and Down syndrome patients, Yoo et
al. using 2-dimensional electrophoresis and MALDI-Tof, described an
increase in the content of three VDAC1 isoforms, which differed in
their isoelectric points [52]. However, no information regarding the
type and site of phosphorylation was presented. In hippocampal ex-
tracts of transgenic mice with Alzheimer's disease, there was a signif-
icant increase in the content of both VDAC1 and VDAC1 threonine-
phosphorylated at an epitope susceptible to phosphorylation by
GSK3β [53]. At the same time, the content of mitochondria-
associated hexokinase I was decreased, rendering the mitochondria
more prone to release proapoptotic factors through VDAC. In cultures
of SH-SY5Y neuroblastoma cells, Aβ1–42 (a amyloid-β-derived diffus-
ible ligand) inhibited Akt activation and consequently prevented
phosphorylation and inactivation of GSK3β, resulting in increased
phosphorylation of VDAC1. These data suggest that VDAC1 phosphor-
ylation is involved in the genesis of apoptosis in brain of Alzheimer
disease patients.
These studies show a relationship between phosphorylation of
VDACs and apoptosis but not a direct cause–effect relationship. Sever-
al questions regarding the isoform of VDACs, the site and type ofVDAC phosphorylation, as well as the mechanism of apoptosis still re-
main open. If VDAC is not a component of the mPTP, how does VDAC
phosphorylation lead to apoptosis? Clearly, further studies are re-
quired. Knowledge of all sites phosphorylated under physiological/
pathophysiological conditions in VDACs, to be determined by mass
spectrometric methods, should provide a platform for logical experi-
mental approaches to the role of VDAC phosphorylation in mitochon-
drial metabolism.
2.3. Posttranslational modiﬁcation of VDACs by acetylation
The knowledge of role of the two types of protein N-acetylation,
i.e., N-terminal and lysine epsilon acetylation, in metabolic regulation
is relatively new and is on the rise. Using novel methods and ap-
proaches, it is estimated that in humans (HeLa cells) approximately
85% of the proteins may be N-terminally acetylated [34,54]. Nα-
acetylation is a common cotranslational – and a rather rare posttrans-
lational – process catalyzed by the highly conserved N-terminal acet-
yltransferases, which differ in their speciﬁcity towards the N-terminal
amino acid [55]. Although N-terminal acetylation is considered irre-
versible, recent data have shown that some of the proteins are incom-
pletely Nα-acetylated [56]. The signiﬁcance of N-terminal acetylation
in cell metabolism is not completely understood; it is thought to af-
fect protein activity, stability, assembly, and intracellular location
[34,57]. Recently it has been shown that Nα-acetylation is regulated
by the availability of acetyl-CoA and changes in acetyl-CoA content
causes directional changes in N-terminally acetylated proteins [58].
The authors found that Bcl-xL overexpression in HeLa cells lowers
the content of acetyl-CoA and Nα-acetylated proteins that is restored
by addition of acetyl-CoA precursors such as acetate and citrate and at
the same time confers sensitivity to apoptotic stimuli [58]. These data
provide a link between metabolism, N-terminal acetylation, and sen-
sitization to apoptosis.
We previously reported that in rat liver mitochondrial outer mem-
brane the N-terminal methionine from VDAC1 is removed and the
new amino terminal alanine is acetylated [19]. The relevance of this
N-terminal acetylation to the reported role of VADC1 remains to be de-
termined. In contrast, both VDAC 2 and VDAC3 retain their predicted N-
terminal methionine and are not N-terminally acetylated [19].
In contrast to the analysis of Nα-acetylation that was hampered
by lack of facile and selective enrichment methods, the availability
of epsilon acetyl-lysine antibodies enormously increased the speed
by which lysine acetylated proteins are identiﬁed. ε-Lysine acetyla-
tion occurs postranslationally and is catalyzed by protein acetyltrans-
ferases (PATs) localized in nucleus, cytosol, and mitochondria. The
direct demonstration of the presence of protein acetyltransferase in
mitochondria is still lacking; however, the fact that mitochondrially-
encoded proteins are acetylated makes the presence of protein acet-
yltransferase in mitochondria highly likely [24]. Lysine deacetylation
is catalyzed by histone deacetylases (HDACs) and NAD+-dependent
deacetylases (sirtuins) [26,35–39]. And mitochondria contain the
NAD+-dependent Sirt3, Sirt4, and Sirt5 protein deacetylases.
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documented for histones but understanding of its role in intermedi-
ary metabolism is burgeoning [59–62]. A compilation of data regard-
ing the acetylation of the three different VDAC isoforms is presented
in Table 2. All data are obtained from global proteomic studies of
acetyl-lysine enriched fractions.
VDAC1 was found to be multiply acetylated in mouse liver but in
different positions in two separate studies [24,25]. In a global proteo-
mic approach, Kim et al. found that in liver of fed and starved mice
VDAC1 is acetylated on lysines in positions 33, 41, 74, and 234 [24].
In a similar study of the effect of calorie restriction, Schwer et al.
found that in mouse liver VDAC1 was lysine-acetylated in positions
41, 122, 132 [25]. However, no signiﬁcant quantitative differences in
VDAC1 acetylation were found between fed and starved and fed and
calorie restricted animals, respectively. In addition to the above men-
tioned sites, VDAC1 also was found to be acetylated on lysine 237 in
mouse liver and heart [63].
In mouse liver, VDAC2 also was found to be acetylated; acetylation
of lysine 32 and 75 was documented in Ref. [24] and on lysine 121 in
Ref. [25]. Again, no differences in acetylation between fed and starved
and fed and calorie-restricted mice were observed.
In contrast to VDAC1 and VDAC2, acetylation of VDAC3 on lysine
20, 61, and 226 was found only in livers of starved but not of fed
mice [24]. Schwer et al. identiﬁed lysine 63 and 109 as being acetylat-
ed in mouse liver, with no differences between fed and calorie-
restricted animals [25]. None of the above studies addressed the po-
tential physiological effect of VDAC acetylation.
In human liver mitochondria, VDAC1 and VDAC3 are found to be
acetylated in position 28 [26]. The amino acid sequence of the acety-
lated dodecapeptide in human VDAC1 and 3 differ in three amino acid
residues.
3. Conclusion and perspectives
VDAC is the most abundant mitochondrial outer membrane pro-
tein and is considered as the “gatekeeper or mitochondrial governa-
tor” [64]. Yet relatively little is known about its regulation. VDAC
plays a pivotal role in mitochondrial function including metabolite
and energy (ADP/ATP) exchange and utilization of ATP by hexokinase
bound to VDAC, docking of cytosolic and intermembrane space pro-
teins, and apoptosis. Moreover, these functions are modiﬁed by post-
translational modiﬁcation. Here, we examined the posttranslational
modiﬁcations of VDAC isoforms by phosphorylation and N-terminal-
and lysine acetylation, and where it has been studied, discussed
their physiologic relevance.
All three VDAC isoforms are modiﬁed by both phosphorylation
and acetylation on multiple sites. Future studies most certainly will
reveal an increase in the number of modiﬁed sites as well as the
type of modiﬁcation. The challenge for future studies is to put these
modiﬁcations in a physiological perspective by altering the modiﬁed
site(s) and determining the physiological outcome of these muta-
tions. Considering that the different functions of VDACs are depen-
dent on or are modiﬁed by the presence of other proteins, this
further increases the complexity of this task.
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